CYP2E1 expression and activity in the liver are increased in humans and in animal models of NAFLD, which is considered to be the critical “hit” in the transition from benign steatosis to steatohepatitis [34]. The gene discussed is CYP2E1; the disease is metabolic dysfunction-associated steatotic liver disease.